GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zentalis Pharmaceuticals Inc (NAS:ZNTL) » Definitions » Beneish M-Score

ZNTL (Zentalis Pharmaceuticals) Beneish M-Score : -3.79 (As of Jul. 03, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Zentalis Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.79 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zentalis Pharmaceuticals's Beneish M-Score or its related term are showing as below:

ZNTL' s Beneish M-Score Range Over the Past 10 Years
Min: -3.79   Med: -3.79   Max: -3.79
Current: -3.79

During the past 7 years, the highest Beneish M-Score of Zentalis Pharmaceuticals was -3.79. The lowest was -3.79. And the median was -3.79.


Zentalis Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Zentalis Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentalis Pharmaceuticals Beneish M-Score Chart

Zentalis Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial - - - - -

Zentalis Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -3.79

Competitive Comparison of Zentalis Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Zentalis Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zentalis Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zentalis Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zentalis Pharmaceuticals's Beneish M-Score falls into.


;
;

Zentalis Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zentalis Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 0.6529+0.892 * 0.6624+0.115 * 0.9612
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.9418+4.679 * -0.127681-0.327 * 1.3126
=-3.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0 + 26.865 + 0 + 0 = $26.87 Mil.
Gross Profit was 0 + 26.865 + 0 + 0 = $26.87 Mil.
Total Current Assets was $342.88 Mil.
Total Assets was $384.02 Mil.
Property, Plant and Equipment(Net PPE) was $35.17 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.23 Mil.
Selling, General, & Admin. Expense(SGA) was $81.96 Mil.
Total Current Liabilities was $49.43 Mil.
Long-Term Debt & Capital Lease Obligation was $38.65 Mil.
Net Income was -48.279 + -47.472 + -40.158 + -88.277 = $-224.19 Mil.
Non Operating Income was -10.452 + -1.564 + 11.247 + -22.863 = $-23.63 Mil.
Cash Flow from Operations was -32.636 + -39.702 + -44.045 + -35.139 = $-151.52 Mil.
Total Receivables was $0.00 Mil.
Revenue was 40.56 + 0 + 0 + 0 = $40.56 Mil.
Gross Profit was 40.56 + 0 + 0 + 0 = $40.56 Mil.
Total Current Assets was $503.81 Mil.
Total Assets was $557.48 Mil.
Property, Plant and Equipment(Net PPE) was $40.41 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.35 Mil.
Selling, General, & Admin. Expense(SGA) was $63.72 Mil.
Total Current Liabilities was $54.80 Mil.
Long-Term Debt & Capital Lease Obligation was $42.62 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 26.865) / (0 / 40.56)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(40.56 / 40.56) / (26.865 / 26.865)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (342.882 + 35.172) / 384.021) / (1 - (503.806 + 40.405) / 557.479)
=0.015538 / 0.0238
=0.6529

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=26.865 / 40.56
=0.6624

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.353 / (1.353 + 40.405)) / (1.227 / (1.227 + 35.172))
=0.032401 / 0.03371
=0.9612

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(81.955 / 26.865) / (63.722 / 40.56)
=3.050623 / 1.571055
=1.9418

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((38.651 + 49.43) / 384.021) / ((42.616 + 54.798) / 557.479)
=0.229365 / 0.17474
=1.3126

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-224.186 - -23.632 - -151.522) / 384.021
=-0.127681

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zentalis Pharmaceuticals has a M-score of -3.79 suggests that the company is unlikely to be a manipulator.


Zentalis Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zentalis Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zentalis Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
10275 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Executives
Andrea Paul officer: General Counsel 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jan Skvarka director C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Cam Gallagher director 6042 CORNERSTONE CT. WEST, SUITE B, SAN DIEGO CA 92121
Diana Hausman director C/O ONCOTHYREON INC., 2601 FOURTH AVE, SUITE 500, SEATTLE WA 98121
Melissa B, Epperly officer: Chief Financial Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Kimberly Blackwell director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Carrie Brownstein officer: Chief Medical Officer 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Kevin D. Bunker officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Iris Roth officer: Chief Operating Officer C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Anthony Y Sun director, officer: President & CEO C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Alexis Pinto officer: Chief Legal Officer C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Dimitris Voliotis officer: SVP, Clinical Development C/O ZENTALIS PHARMACEUTICALS, INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Enoch Kariuki director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901